AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Cardiac Electrophysiological Study
Phase 2
Completed
- Conditions
- Atrial Flutter
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT00616629
- Locations
- 🇸🇪
Research Site, Ŏrebro, Sweden
Schizophrenic Patients Taking Part in Integrated Care Program
Terminated
- Conditions
- SchizophreniaSchizoaffective DisorderSchizophreni-form DisorderDelusional DisorderPsychotic Disorder Not Otherwise Specified
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00617214
- Locations
- 🇩🇪
Research Site, Zittau, Germany
AZD9773 Dose Escalation Study
Phase 2
Completed
- Conditions
- Severe Sepsis
- Interventions
- Drug: AZD9773 (CytoFab)Other: Placebo
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00615017
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients
Phase 1
Completed
- Conditions
- CancerTumorsCarcinoma
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00613652
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 572
- Registration Number
- NCT00614939
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00612794
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Symbicort in Chronic Obstruktive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2008-02-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18014
- Registration Number
- NCT00612976
Symbicort in Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64730
- Registration Number
- NCT00611520
Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions
Completed
- Conditions
- Gastrointestinal Diseases
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 29586
- Registration Number
- NCT00612027
Symptoms and Endoscopic Results in Consideration of Pretreatment
Completed
- Conditions
- Gastrointestinal Diseases
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16255
- Registration Number
- NCT00612404
© Copyright 2025. All Rights Reserved by MedPath